Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News TherapeuticsMD Inc TXMD

Healthcare
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD... see more

Recent & Breaking News (NDAQ:TXMD)

TherapeuticsMD Announces Third Quarter 2024 Financial Results

Business Wire 10 days ago

TherapeuticsMD Announces Second Quarter 2024 Financial Results

Business Wire August 12, 2024

TherapeuticsMD Announces First Quarter 2024 Financial Results

Business Wire May 10, 2024

TherapeuticsMD Announces Full Year 2023 Financial Results

Business Wire March 29, 2024

TherapeuticsMD Announces Third Quarter 2023 Financial Results

Business Wire November 14, 2023

TherapeuticsMD Announces Second Quarter 2023 Financial Results

Business Wire August 14, 2023

TherapeuticsMD Announces First Quarter 2023 Financial Results

Business Wire May 15, 2023

TherapeuticsMD Announces Full Year 2022 Financial Results and Provides Update on Business Model Transition

Business Wire April 7, 2023

TherapeuticsMD Completes Transaction to License Its Products to Mayne Pharma

Business Wire January 3, 2023

TherapeuticsMD Announces Definitive Agreements to License its Products to Mayne Pharma

Business Wire December 4, 2022

TherapeuticsMD Announces Third Quarter 2022 Financial Results

Business Wire November 14, 2022

TherapeuticsMD Announces Additional $7 Million Private Placement

Business Wire October 31, 2022

TherapeuticsMD Appoints Dr. Brian Bernick and Mr. Mark Glickman as Interim Co-Chief Executive Officers

Business Wire September 12, 2022

TherapeuticsMD Announces Second Quarter 2022 Financial Results

Business Wire August 15, 2022

TherapeuticsMD to Report Second Quarter 2022 Financial Results on August 15, 2022

Business Wire August 8, 2022

TherapeuticsMD Secures $15 Million Equity Investment from Rubric Capital

Business Wire August 1, 2022

TherapeuticsMD Announces Expiration of Tender Offer

Business Wire July 13, 2022

EW Healthcare Partners Announces Extension of TherapeuticsMD Tender Offer

PR Newswire July 6, 2022

EW Healthcare Partners Announces Commencement of the Tender Offer for All Outstanding Shares of TherapeuticsMD

PR Newswire June 6, 2022

SHAREHOLDER UPDATE: Halper Sadeh LLP Investigates VMW, TPTX, CTT, TXMD

PR Newswire June 6, 2022